Clinical pharmacology, efficacy and safety of atazanavir: a review. - Wikidata - wikimedia - TriplyDB

Clinical pharmacology, efficacy and safety of atazanavir: a review.

Clinical pharmacology, efficacy and safety of atazanavir: a review.

http://www.wikidata.org/entity/Q37622972

about

Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study.Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study.Vertigo/dizziness as a Drugs' adverse reaction.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.Liver involvement in human immunodeficiency virus infection.Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.Revealing the metabolic sites of atazanavir in human by parallel administrations of D-atazanavir analogs.Incidence of hyperbilirubinemia and jaundice due to atazanavir in a cohort of Hispanic patients.Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.Identification and structural elucidation of in vitro metabolites of atazanavir by HPLC and tandem mass spectrometry.Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.Effect of hepatitis B and C clearance on atazanavir exposure.CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.

P2860

Q34032348-470E65DD-0721-4BD2-9E65-3385662775BE Q35079510-878583BF-FFCF-49F9-B55B-645BC996A14B Q35908862-97A4D8AB-3598-4B90-8548-96793339003D Q36634838-EF485D9C-AD80-4718-A717-8FB8AC5CF512 Q37369622-F57ACD14-E398-46E9-A159-D15BB507CBEB Q37866298-549943B8-89C1-41A5-8202-7D100A623EDA Q38852184-170DDCF0-A9AA-47EB-B3D0-BF2C82011DE0 Q39074109-6BB703B1-9A8E-446A-A59D-05B13B67DD9D Q41666586-D32C5DEE-FBAB-4146-AA31-9966742C962C Q42229879-033B027B-FE00-4FA1-884B-2A6A1CB8594C Q42265837-2A058152-FDBE-4D34-A593-4C0E1AFF5368 Q43240844-62306FD2-676D-478C-B6E3-B9FFECFA5CFB Q43461603-9C9B7E08-7674-488E-B0CF-55C8FFBD6BB5 Q43654216-31CFC6E8-0DAC-45E3-91D9-C6799EA5E0DF Q44401027-3289FC3A-1B29-4A98-AB01-137BB5A9FACC Q46016007-2E9ABC03-82E6-4253-A239-1061BBAC4388 Q50975705-9D5348EE-80E7-4535-8B2B-75B04FCD9711 Q51631938-C8482DC2-B584-435C-8A38-65C2478E9D2B

P2860

Clinical pharmacology, efficacy and safety of atazanavir: a review.

http://www.wikidata.org/entity/Q37622972

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Clinical pharmacology, efficacy and safety of atazanavir: a review.

@en

Clinical pharmacology, efficacy and safety of atazanavir: a review.

@nl

type

label

Clinical pharmacology, efficacy and safety of atazanavir: a review.

@en

Clinical pharmacology, efficacy and safety of atazanavir: a review.

@nl

prefLabel

Clinical pharmacology, efficacy and safety of atazanavir: a review.

@en

Clinical pharmacology, efficacy and safety of atazanavir: a review.

@nl

P1433

Q37622972-B536FE58-2B32-40F2-B5DA-43555411C2A3

P1476

Q37622972-EC649994-60C6-4FE1-9C93-4DB9910F4284

P2093

Q37622972-003BD762-4627-4B6E-B176-35096FC11F7C

Q37622972-3F52B7F1-1770-407A-8745-8660AD0AC65C

Q37622972-B0B29E01-71AA-4665-91AD-F4AC974A6CC2

Q37622972-D511AC76-F6B9-43A5-A6FF-9D77440810F0

P2860

Q37622972-04DB7FCF-3178-4500-B354-F2648F45307E

Q37622972-0722D85B-2587-4497-8651-082957EDBFF6

Q37622972-09844415-F586-48D2-89C0-82136C7717B4

Q37622972-133EF30D-280A-4C16-AB40-B35B7EA8ADB4

Q37622972-15459695-2E5C-4FF0-993E-1A829BBCB0FE

Q37622972-1AB40443-6F2C-4B52-A45C-97B2BB364C1F

Q37622972-1BEF3B59-258E-4877-B3C1-5CB41ACD0C6C

Q37622972-1FC9A03A-95EE-45A2-8E63-688358C4AB46

Q37622972-22BFFCB1-5791-490E-AFC1-7567A1F1A904

Q37622972-244FC2CD-DFDD-4CBE-B43E-68F1A1B53041

P304

Q37622972-A08F1FE9-C82F-4AB6-BF1C-B43E5EDBDC0A

P31

Q37622972-C7650963-F735-48B2-9443-2678775AC375

P356

Q37622972-5E77657D-F7F9-4D42-8CBA-579B1239CE3E

P407

Q37622972-F25306FC-57C4-4C67-83E4-DD9B4B904F7C

P433

Q37622972-3A63475B-3F1C-449D-B78A-0795C1E13437

P478

Q37622972-8895C5A8-9D26-4278-8C39-6F782AEA873C

P50

Q37622972-D960C981-EBAD-487D-B075-118643C9853F

P577

Q37622972-98B9FEE0-8529-4500-AC43-DE326B803995

P698

Q37622972-925CD62E-ADCA-43B0-A6F1-100B2C4F7C1A

P921

Q37622972-B67AF456-C160-446F-AABC-C3B9341105CD

P356

17425250903321514

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

Clinical pharmacology, efficacy and safety of atazanavir: a review

@en

P2093

Annick Ruffault

http://www.w3.org/2001/XMLSchema#string

Danièle Bentué-Ferrer

http://www.w3.org/2001/XMLSchema#string

Eric Bellissant

http://www.w3.org/2001/XMLSchema#string

Olivier Tribut

http://www.w3.org/2001/XMLSchema#string

P2860

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.

Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.

Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones

No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.

Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection

P304

1455-1468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425250903321514

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Cédric Arvieux

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19863454

http://www.w3.org/2001/XMLSchema#string

P921